tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2023 Dec 1.
doi: 10.1080/14760584.2023.2290691. Online ahead of print. Influenza B virus neuraminidase: a potential target for next-generation vaccines?
Thi Hoai Thu Do[SUP] 1 [/SUP], Adam K Wheatley[SUP] 1 [/SUP], Stephen J Kent[SUP] 1 2 [/SUP], Marios Koutsakos[SUP] 1 [/SUP]
Affiliations
Introduction: Influenza B viruses (IBV) cause a significant health and economic burden annually. Due to lower antigenic drift rate, less extensive antigenic diversity, and lack of animal reservoirs, the development of highly effective universal vaccines against IBV might be in reach. Current seasonal influenza vaccines are formulated to induce antibodies against the Hemagglutinin (HA) protein, but their effectiveness is reduced by mismatch between vaccine and circulating strains.
Areas covered: Given antibodies against the Neuraminidase (NA) have been associated with protection during influenza infection, there is considerable interest in the development of NA-based influenza vaccines. This review summarizes insights into the role of NA-based immunity against IBV and highlights knowledge gaps that should be addressed to inform the design of next-generation influenza B vaccines. We discuss how antibodies recognize broadly cross-reactive epitopes on the NA and the lack of understanding of IBV NA antigenic evolution which would benefit vaccine development in the future.
Expert opinion: Demonstrating NA antibodies as correlates of protection for IBV in humans would be paramount. Determining the extent of IBV NA antigenic evolution will be informative. Finally, it will be critical to determine optimal strategies for incorporating the appropriate NA antigens in existing clinically approved vaccine formulations.
Keywords: Antibodies; influenza B virus; neuraminidase; universal vaccines.
. 2023 Dec 1.
doi: 10.1080/14760584.2023.2290691. Online ahead of print. Influenza B virus neuraminidase: a potential target for next-generation vaccines?
Thi Hoai Thu Do[SUP] 1 [/SUP], Adam K Wheatley[SUP] 1 [/SUP], Stephen J Kent[SUP] 1 2 [/SUP], Marios Koutsakos[SUP] 1 [/SUP]
Affiliations
- PMID: 38037386
- DOI: 10.1080/14760584.2023.2290691
Introduction: Influenza B viruses (IBV) cause a significant health and economic burden annually. Due to lower antigenic drift rate, less extensive antigenic diversity, and lack of animal reservoirs, the development of highly effective universal vaccines against IBV might be in reach. Current seasonal influenza vaccines are formulated to induce antibodies against the Hemagglutinin (HA) protein, but their effectiveness is reduced by mismatch between vaccine and circulating strains.
Areas covered: Given antibodies against the Neuraminidase (NA) have been associated with protection during influenza infection, there is considerable interest in the development of NA-based influenza vaccines. This review summarizes insights into the role of NA-based immunity against IBV and highlights knowledge gaps that should be addressed to inform the design of next-generation influenza B vaccines. We discuss how antibodies recognize broadly cross-reactive epitopes on the NA and the lack of understanding of IBV NA antigenic evolution which would benefit vaccine development in the future.
Expert opinion: Demonstrating NA antibodies as correlates of protection for IBV in humans would be paramount. Determining the extent of IBV NA antigenic evolution will be informative. Finally, it will be critical to determine optimal strategies for incorporating the appropriate NA antigens in existing clinically approved vaccine formulations.
Keywords: Antibodies; influenza B virus; neuraminidase; universal vaccines.